Adial Pharmaceuticals- Warrants (31/07/2023) Operating Income

As of the most recent data (June 2026), ADILW shows a operating income of $-58M. That compares with $-8.3M in the prior-year period — down 594.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ADILW's operating income is now $-58M (was $-8.3M) — a 594.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Adial Pharmaceuticals- Warrants (31/07/2023) is outperforming or lagging.

Tracking ADILW's operating income over time shows whether Adial Pharmaceuticals- Warrants (31/07/2023) is scaling, shrinking, or reshaping that part of the business. The current reading is $-58M That compares with $-8.3M in the prior-year period — down 594.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Adial Pharmaceuticals- Warrants (31/07/2023)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-58M) with ownership activity and broader fundamentals.

Adial Pharmaceuticals- Warrants (31/07/2023)'s operating income is $-58M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.